Introduction: Arrhythmic Substrate in HCM, from Tissue to the Single Myocyte
============================================================================

Hypertrophic cardiomyopathy (HCM) is the most common monogenic inheritable heart disease ([@B51]; [@B32]; [@B7]), with a prevalence of 1:500. HCM is a leading cause of sudden cardiac death in the young ([@B51]) and a prevalent cause of heart failure and stroke in all age groups ([@B50]). Mutations in genes coding for sarcomeric proteins are found in over 60% of patients with HCM, the most commonly involved genes being *MYH7* (β-myosin heavy-chain) and *MYBPC3* (cardiac myosin-binding protein-C). Increased ventricular arrhythmogenesis is one of the main pathophysiological features of this disease ([@B57]) and is responsible for the heightened risk of lethal arrhythmias in HCM patients. Despite being only mildly symptomatic in about 2/3 of patients ([@B52]), HCM can slowly progress toward heart failure, either with preserved or reduced ejection fraction, due to worsening of diastolic and/or systolic function ([@B56]). Accumulation of intra-myocardial fibrosis and replacement scars underlies heart failure progression and represents a substrate for sustained arrhythmias ([@B31]). Late gadolinium enhancement (LGE) at cardiac magnetic resonance, an index of cardiac fibrosis, is widely used to stratify the severity of disease progression ([@B7]) and to help defining the risk of lethal arrhythmias and terminal heart failure ([@B14]). However, LGE only identifies extensive replacement scars and well predicts the risk of arrhythmias only at the advanced stages of the disease ([@B14]). Replacement fibrosis in HCM appears to be related with local myocardial ischemia, caused by microvascular dysfunction ([@B74]), as myocardial tissue in regions with severe microvascular ischemia is slowly replaced by collagen. The degree of microvascular dysfunction, as assessed by positron emission tomography with labeled ammonia measuring the reduction of local myocardial blood flow, is related with patient outcome, including the risk of arrhythmias at advanced disease stages ([@B13]). Replacement fibrosis and microvascular ischemia are strongly related with the risk of ventricular arrhythmias because they create a stable substrate for reentry circuits, the main drivers of sustained ventricular arrhythmias ([@B63]). In order for a reentry circuit to be established, an area of conduction block adjacent to a region of slower, unidirectional conduction is needed: indeed, in HCM myocardium, patchy replacement fibrosis generates areas of no-conduction, while the surrounding ischemic regions (due to microvascular dysfunction) cause slower, altered conduction, and transient local alterations of repolarization ([@B40]). Following these observation, the simplest conclusion would be that structural left ventricular remodeling at macroscopic myocardial level, featuring replacement fibrosis and microvascular dysfunction, is the main determinant of arrhythmias in HCM. However, a clear relationship between fibrosis (measured with LGE), microvascular dysfunction (measured by PET) and arrhythmic risk is observed only in the minority of patients (10--15%) that experience a slow progression toward end-stage HCM, an highly arrhythmogenic condition not unlike terminal ischemic heart failure, thus requiring aggressive preventive strategies ([@B65]). On the contrary, the majority of sudden cardiac death events due to lethal ventricular arrhythmias occur in patients at earlier stages of disease progression, often in the absence of marked structural abnormalities besides left-ventricular (LV) hypertrophy, also in very young patients ([@B54]). In early stages of hypertrophic cardiomyopathies, replacement scars are absent and only microscopic intramyocardial fibrosis is present, and its extent can be assessed by CMR using T1-mapping ([@B21]) or extracellular volume (ECV) measurements with gadolinium contrast, both altered even before the onset of hypertrophy in HCM-mutation carriers ([@B37]). However, the link between the degree of ECV expansion and the risk of arrhythmias in early stage HCM is still uncertain ([@B8]). Therefore, arrhythmias in HCM cannot be the sole consequence of the substrate for re-entry circuits at tissue level. On the contrary, the main determinants of arrhythmogenesis in HCM are to be found within the affected cardiomyocytes, a consequence of the alterations of ion currents and intracellular Ca^2+^ handling that occur as a part of HCM-related ventricular cardiomyocyte remodeling ([@B16]; [@B17]; [@B25]; [@B28]). Indeed, from a pathophysiological standpoint, the vast majority of ventricular tachycardia episodes begin with one or more premature ectopic ventricular beats ([@B79]). Premature ventricular activations are essential to initiate the abnormal rotating conduction of the re-entry circuits in the presence of an appropriate substrate. Even in the presence of extended structural alterations, such as large scars and diffuse interstitial fibrosis, ectopic premature activations initiating in abnormal cardiomyocytes could be essential triggers to initiate the re-entry that is then maintained by the structural substrate. Interestingly, ectopic activity is the primary event producing local unidirectional block, which is an essential prerequisite for the establishment of a re-entry circuit. Ectopic ventricular beats are very common in HCM patients ([@B1]) and originate from the premature spontaneous premature activation of a group of adjacent synchronized ventricular cardiomyocytes within the ventricular mass, which is then propagated to the whole surrounding ventricular mass, often in a chaotic and unpredictable manner ([@B68]). Early- and delayed- afterdepolarizations are the cellular arrhythmic events that may result into the spontaneous generation of premature action potentials in the affected cardiomyocytes. The following part of this review will illustrate how an increased likelihood of early and delayed after-depolarizations in HCM cardiomyocytes is a consequence of specific alterations of ion currents and intracellular Ca^2+^-handling.

Materials and Methods {#s1}
=====================

Most of the results presented in the figures were previously published in [@B16] and in [@B28]. Previously unpublished results are presented in **Figures [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}**. Cardiomyocytes and intact trabeculae were freshly isolated as previously described ([@B16]; [@B28]), using surgical upper inter-ventricular septum samples excised from HCM patients who underwent myectomy operation for the relief of severe symptoms due to obstruction of the LV outflow tract. Notably, all recruited patients had preserved systolic function but impaired diastole and most of them have a history of documented non-sustained ventricular tachycardia at Holter monitoring. The experimental protocols were approved by the ethical committee of Careggi University-Hospital of Florence (2006/0024713, renewed May 2009; 2013/0035305). In single cardiomyocytes, APs and Ca^2+^ transients were simultaneously measured using combined patch-clamp and Ca^2+^-fluorescence measurements, during stimulation at different frequencies. Cell capacitance was measured in voltage-clamp mode. Isometric force was measured from intact trabeculae during electrical field stimulation. Cells/trabeculae were exposed to test drugs for at least 5 min prior to recordings. Number of cells/trabeculae for each comparison, as well as the statistical tests used, are indicated in the respective figure legends.

Remodeling of Ion Currents in HCM Cardiomyocytes
================================================

Hypertrophic cardiomyopathy (HCM) cellular pathophysiology is characterized by the interplay between primary alterations (direct consequences of causal sarcomeric mutations altering myofilament function) and a large number of secondary myocardial modifications, comprising cellular electrophysiological remodeling (changes in transmembrane currents) and alterations of intracellular Ca^2+^ handling \[Ca^2+^ transients and diastolic (Ca^2+^)\] ([@B16]; [@B17]; [@B25]; [@B28]). Due to the profound electrophysiological differences between mouse and human cardiomyocytes, studies conducted on transgenic rodent models did not help to identify the features if ion-current remodeling occurring in HCM myocardium ([@B80]). To overcome this limitation, we investigated the abnormalities of electrical function, Ca^2+^ handling and contraction of human HCM myocardium as coexisting contributing factors for contractile dysfunction and arrhythmias in this disease ([@B16]). We used isolated myocytes and intact trabeculae from fresh myocardial samples from the interventricular septum of HCM patients undergoing surgical myectomy operation for refractory symptoms related to severe obstruction of the left ventricular outflow tract, compared with septal samples from non-hypertrophic surgical patients ([@B16]; [@B28]). Overall, we performed patch-clamp and ion-fluorescence studies in over 200 cardiomyocytes from 43 HCM patients ([@B16]; [@B28]). Results of patch clamp studies in isolated ventricular cardiomyocytes showed that the duration of action potentials (APD), recorded at various pacing rates, was significantly prolonged in cardiomyocytes from HCM cardiomyocytes, with regards to controls (**Figure [1A](#F1){ref-type="fig"}**). As expected, prolongation of APD was associated with prolonged QTc in patients from the HCM cohort (average QTc = 470 ms). Of note, a recent large multi-center observational study on HCM patients suggested that mild QT prolongation is a common observation in those patients ([@B41]). Prolonged APD was the main determinant of the increased risk of early afterdepolarisations (EADs) ([@B3]), that is, spontaneous depolarisations occurring before the end of the repolarization phase: the occurrence of this type of cellular arrhythmias was 6-fold more frequent in HCM vs. control cardiomyocytes (**Figure [1B](#F1){ref-type="fig"}**). Interestingly, the frequency of EADs and the degree of APD prolongation went hand in hand with the incidence of ventricular arrhythmias in patients: patients whose cells show markedly prolonged APDs had a higher rate of documented non-sustained ventricular tachycardia at 24 h ECG ([@B16]; **Figure [1C](#F1){ref-type="fig"}**). APD prolongation in HCM cardiomyocytes is caused by a combination of decreased repolarizing potassium currents and increased depolarizing (Ca^2+^ and Na^+^) currents: transient outward K^+^ current (I~to~), inward-rectifier current (I~K1~), as well as delayed rectifier K^+^ currents were significantly reduced, while both L-Type Ca^2+^ current (I~CaL~) and late Na^+^ current (I~NaL~) were increased in HCM cells, as compared to control cardiomyocytes ([@B16]; **Figures [1D](#F1){ref-type="fig"}--[H](#F1){ref-type="fig"}**). Pathological changes of the density of ion currents in HCM cardiomyocytes were caused by different mechanisms. The reduced density of potassium currents in HCM cardiomyocytes was the consequence of the lower levels of expression of K^+^ channel genes (**Figures [1D,E](#F1){ref-type="fig"}**), as observed in several human and animal models of cardiac hypertrophy and heart failure ([@B66]), including heart failure with preserved ejection fraction (HFpEF) ([@B15]). In line with other models of LV hypertrophy and diastolic dysfunction ([@B15]), in human HCM myocardium the ion-channel genes with the most severely depressed expression were I~to~ and I~K1~ ([@B16]): this might be a consequence of the increased activity of Ca^2+^/calmodulin-dependent protein-kinase II (CaMKII) in HCM cardiomyocytes ([@B16]), which is able to down-regulate I~to~ and I~K1~ currents by reducing the expression of functional channels ([@B82]). Moreover, the down-regulation of I~K1~ (Kir2.1) may also be related with the increased expression of micro-RNA miR-1 ([@B85]) observed in HCM specimens ([@B16]). The small increase of I~CaL~ density in HCM cardiomyocytes is likely determined by the slightly higher expression of CACNA1.2 gene and CaV1.2 protein (**Figures [1F](#F1){ref-type="fig"}--[H](#F1){ref-type="fig"}**). In addition, the inactivation kinetics of I~CaL~ is markedly slower in HCM vs. control cardiomyocytes ([@B16]; [@B28]; **Figure [1G](#F1){ref-type="fig"}**), contributing to prolong I~CaL~ activation during the AP plateau, thus delaying repolarization. Interestingly, we found that the slower inactivation of I~CaL~ observed in HCM cardiomyocytes may be related with the increased phosphorylation of L-type Ca^2+^ channel β-subunit by CaMKII ([@B39]), observed in HCM myocardium (**Figure [3](#F3){ref-type="fig"}**). Finally, I~NaL~ was consistently increased in all studied HCM myocytes: I~NaL~ integral (estimating the total Na^+^ flow upon a single current activation) was 2--3 times larger in HCM as compared with control cells (**Figure [1J](#F1){ref-type="fig"}**). As I~NaL~ is the slowly inactivating or non-inactivating component of Na^+^ current that remains active as a depolarizing current during the AP plateau, it directly contributes to prolong APD in HCM cardiomyocytes, as previously shown in human and animal models of cardiac hypertrophy and heart failure ([@B49]; [@B62]; [@B64]). The aforementioned changes in Ca^2+^, late Na^+^ and K^+^ current densities were quantitatively introduced into validated mathematical models of human ventricular myocyte ([@B33]; [@B16]; [@B60]): these studies confirmed that the observed ion current changes are sufficient to explain the prolongation of APD in human HCM cardiomyocytes. Also, modeling studies suggested that increased I~NaL~ plays a pivotal role as determinant of APD prolongation and EADs in HCM ([@B60]), as repolarization reserve is extremely reduced by the down-regulation of K^+^ currents. In support of this hypothesis, we studied the effects of I~NaL~ inhibition by ranolazine ([@B4]) or GS-967 ([@B72]) (a potent and selective I~NaL~ blocker) in HCM cardiomyocytes ([@B16]; [@B28]): I~NaL~ inhibition significantly reduced APD by approximately 30% in all HCM cardiomyocytes (**Figure [1](#F1){ref-type="fig"}**). Of note, ranolazine (at the clinically relevant concentration of 10 μM) and GS-967 (at 0.5 μM) reduced I~NaL~ by 70% in HCM cardiomyocytes. Consistently, the likelyhood of EADs in HCM cardiomyocytes was nearly halved by ranolazine or GS-967. In agreement with the increased role of I~NaL~ as a determinant of APD in the presence of an impaired repolarization reserve, the efficacy of ranolazine in shortening APD was more pronounced at low pacing frequencies and in cells with a longer APD at baseline. Studies in a mathematical cardiomyocyte model ([@B60]) confirmed that inhibition of 70% of I~NaL~ in HCM myocytes is sufficient to reduce APD, abolish EADs and reduce APD dispersion, as experimentally observed with pharmacological blockers.

![Remodeling of ion currents in HCM cardiomyocytes **(A)** Superimposed representative action potentials recorded during stimulation at 0.2 Hz from HCM and control cardiomyocytes. **(B)** Representative recording from an HCM cardiomyocyte paced at 0.2 Hz, showing EADs. Black arrows mark stimuli. Orange arrows mark EADs. **(C)** Occurrence of EADs in 23 cells from patients without NSVT (NSVT-) and 29 from patients with NSVT (NSVT+). **(D)** Representative traces (left, top panel control, bottom panel HCM) and average I~to~ activation curves from control and HCM cardiomyocytes (right panel). **(E)** RNA expression of potassium current genes, relative to GAPDH in control (*N* = 11, gray) and HCM (*N* = 15, black) samples. **(F)** Left: representative I~CaL~ traces at different voltages. Right: I~CaL~ activation curves. **(G)** Superimposed normalized I~CaL~ recordings at 0 mV. **(H)** Protein expression of I~CaL~ and I ~Na~ main channel subunits (Cav1.2 and Nav1.5). **(J)** Representative I~NaL~ traces from control and HCM cardiomyocytes. **(K)** Ranolazine inhibits I~NaL~ in HCM cardiomyocytes: representative I~NaL~ traces from an HCM cardiomyocyte during depolarization to -20 mV in the absence (Basal) or presence of Ran. **(I)** Action potentials at 0.2 Hz from an HCM cardiomyocyte before (Basal) and after exposure to 10 μmol/L ranolazine (Ran). Modified from [@B16] (ref. 19).](fphys-09-01391-g001){#F1}

Remodeling of Ca^2+^ Handling in HCM Cardiomyocytes
===================================================

Notwithstanding the large variabilities observed among different disease models, the common feature that is described in all transgenic animal models, human samples and cellular models of HCM is the sustained increase of diastolic intracellular calcium concentration \[(Ca^2+^)\]~i~ within ventricular cardiomyocytes ([@B42]; [@B34]; [@B5]; [@B30]; [@B45]). The increase of \[Ca^2+^\]~i~ is likely to be a direct consequence of some of the sarcomere mutations that cause the disease and thus it may among the first pathological changes in the hearts of HCM-mutation carriers. Indeed, the majority of HCM-related mutations cause an increase of the Ca^2+^-sensitivity of the myofilaments and determine an increased ATP-consumption by the cardiac sarcomeres ([@B5]), thus reducing the energetic efficiency of force production by the myocardium. Both these primary sarcomeric changes are associated with an increase of \[Ca^2+^\]~i~: the increased myofilament Ca^2+^- sensitivity determines a slower release of Ca^2+^ from Troponin-C that in turn prolongs the decay of Ca^2+^-transients and leads to elevated diastolic \[Ca^2+^\]~i~ ([@B9]). ATP depletion caused by the reduced efficiency of mutated myofilaments can reduce the function of the sarcoplasmic reticulum Ca^2+^-ATPase (SERCA), thus reducing the rate of Ca^2+^ reuptake from the cytosol during relaxation ([@B6]). Regardless of the cause that primarily increases \[Ca^2+^\]~i~, the complex remodeling of the Ca^2+^-handling apparatus in the cardiomyocytes of HCM hearts determines a global alteration of intracellular Ca^2+^ fluxes, ultimately contributing to aggravate Ca^2+^ overload in the cytosol and in the sarcoplasmic reticulum (SR) (**Figure [2](#F2){ref-type="fig"}**).

![Remodeling of Ca^2+^ handling in HCM cardiomyocytes. **(A)** Superimposed representative Ca^2+^~i~ transients recorded during stimulation at 0.2 Hz. from control and HCM cardiomyocytes. **(B)** Continuous recordings of Ca^2+^~i~ transients elicited at 0.2, 0.5, and 1 Hz frequency of stimulation, from a control (above) and an HCM (below) cardiomyocyte. **(C)** Average diastolic Ca^2+^~i~ fluorescence levels at increasing pacing frequencies. **(D)** Representative recording from an HCM cardiomyocyte, showing DADs, occurring in response to spontaneous Ca^2+^ release (calcium waves). Black arrows mark stimuli. Orange arrows mark DADs. **(E)** Ca^2+^ fluorescence traces during the protocol to measure SR Ca^2+^ content with caffeine: superimposed normalized caffeine-induced calcium transients from HCM and control cardiomyocytes. **(F)** SR Ca^2+^ content (left) in control and HCM cardiomyocytes. **(G)** Protein expression of NCX1, SERCA2a, RYR2 and PLB in HCM (*N* = 10) and control (*N* = 10) specimens. **(H)** Superimposed representative Ca^2+^~i~ transients at 0.2 Hz from an HCM cardiomyocyte at baseline and with ranolazine. **(J)** Trains of Ca^2+^~i~ transients elicited at 0.2, 0.5, and 1 Hz in an HCM myocyte before (left) and following (right) exposure to Ran. **(K)** Representative traces of ANG-II florescence (intracellular sodium) during diastole, recorded at steady state stimulation of 0.2, 0.5, and 1 Hz in the absence (black) and presence (red) of 10 μM Ran. **(I)** Representative trains of action potentials elicited at 0.5 Hz at baseline (black traces) and in the presence of GS-967 0.5 μM (red traces). Early after-depolarizations (EADs) are marked by arrows. **(L)** Representative trains of action potentials elicited at 0.5 Hz. Delayed after-depolarizations (DADs) are marked by arrows. Modified from [@B16] and from [@B28].](fphys-09-01391-g002){#F2}

In human HCM cardiomyocytes, abnormalities of APD and ion current were paralleled by marked alterations of intracellular Ca^2+^ handling ([@B16]; [@B28]), as studied by virtue of fluorescence measurements using Ca^2+^-sensitive dyes. Ca^2+^ transient amplitude was similar in HCM and control myocytes. Conversely, Ca^2+^ transient kinetics was significantly slower and intracellular diastolic Ca^2+^ concentration (\[Ca^2+^\]~i~) was higher in HCM cells as compared to control cardiomyocytes, especially at higher rates of stimulation (**Figures [2A--C](#F2){ref-type="fig"}**). The elevated \[Ca^2+^\]~i~ contributed to the abnormally high rate of spontaneous Ca^2+^ releases from the SR observed in HCM myocytes, resulting in diastolic Ca^2+^-waves and delayed after-depolarizations (DADs), thus contributing to cellular arrhythmogenesis (**Figure [2D](#F2){ref-type="fig"}**). Additionally, SR Ca^2+^ content was slightly increased in HCM cardiomyocytes (**Figure [2F](#F2){ref-type="fig"}**), at variance with human and animal models of heart failure with reduced systolic function, where decreased SR Ca^2+^ content and Ca^2+^ transients amplitude are common observations ([@B10]; [@B70]). The altered Ca^2+^ fluxes in HCM myocytes are the result of several concurrent alterations: (i)increased amplitude and slower inactivation kinetics of L-Type Ca^2+^-current (see above), (ii)reduced expression of SERCA and reduced SERCA/phospholamban ratio (**Figure [2G](#F2){ref-type="fig"}**), (iii)loss or disorganization of t-tubules (see below), (iv) increase leakage of Ca^2+^ from the SR, and (v)abnormal function of the Na^+^/Ca^2+^ exchanger (NCX). The latter is the consequence of the increased intracellular concentration of Na^+^ (\[Na^+^\]~i~). In agreement with these results, we calculated a negative shift of the NCX reversal potential (E~NCX~), suggesting increased \[Na^+^\]~i~. Indeed, we directly observed an increase of \[Na^+^\]~i~ in HCM myocytes, as measured in human HCM myocytes using the Na^+^-selective fluorescent dye Asante Natrium Green II (**Figure [2K](#F2){ref-type="fig"}**). Based on this observation, we proposed that enhanced Na^+^ influx mediated by the larger I~NaL~ leads to a sustained increase in cytosolic \[Na^+^\]~i~, providing the driving force for an increased rate of Ca^2+^ entry trough NCX, as previously observed in secondary LV hypertrophy ([@B76]), albeitnot in heart failure. Combined with the increased expression of NCX and the prolongation of APs, this mechanism leads to an increased total Ca^2+^ entry during the plateau of the AP, thus helping HCM cardiomyocytes to maintain normal SR Ca^2+^ load, Ca^2+^ transients amplitude and contractility ([@B83]) despite SERCA down-regulation. This is at variance with reports on human failing cardiomyocytes ([@B10]), where SERCA down-regulation reduces SR Ca^2+^ load and Ca^2+^ release. However, the increased cytosolic \[Na^+^\]~i~ in HCM myocytes also reduces forward-mode NCX activity, thus determining the observed decrease of Ca^2+^ extrusion rate during exposure to caffeine (**Figure [2E](#F2){ref-type="fig"}**) and likely contributing to prolong Ca^2+^ transient decay and increase diastolic \[Ca^2+^\]~i~, in combination with the reduced activity of SERCA. Notably, prolongation of APs likely contributes to reduce Ca^2+^ extrusion through the NCX, as the exchanger can effectively work in forward mode only at diastolic potentials. The central role of the increased I~NaL~ in determining Na^+^ and Ca^2+^ overload in HCM cardiomyocytes is highlighted by the effects of I~NaL~ inhibition by ranolazine or GS-967 ([@B16]; [@B28]). In human HCM cardiomyocytes, besides shortening APD, I~NaL~ inhibition reduced intracellular \[Na^+^\] (**Figure [2K](#F2){ref-type="fig"}**), as directly assessed using fluorescence measurements. The reduction of \[Na^+^\]~i~ shifted E~NCX~ back to positive levels; this in turn led to a potentiation of the forward-mode activity of the NCX (Ca^2+^ extrusion/Na^+^ entry), while it decreased the reverse-mode function (Ca^2+^ entry/Na^+^ extrusion). The enhanced Ca^2+^ extrusion via the NCX resulted in an acceleration of Ca^2+^-transient decay, determined a reduction of diastolic \[Ca^2+^\]~i~, and lessened diastolic \[Ca^2+^\]~i~ rise in response to increases of pacing frequency (**Figures [2H](#F2){ref-type="fig"}--[J](#F2){ref-type="fig"}**). In keeping with these observations, we observed that ranolazine hastened the decay of caffeine-induced Ca^2+^ transients and slightly reduced SR Ca^2+^-content in HCM cardiomyocytes ([@B16]). Interestingly, the reduction of diastolic \[Ca^2+^\]~i~ by ranolazine or GS-967 reduced the occurrence of spontaneous diastolic Ca^2+^ waves, DADs and triggered activity (**Figures [2I](#F2){ref-type="fig"}--[L](#F2){ref-type="fig"}**).

Intracellular Ca^2+^ overload negatively affected diastolic function in HCM myocardium: kinetics of relaxation was slower in HCM vs. control trabeculae and diastolic tension was higher, especially at high stimulation frequencies. Ranolazine and GS-967, by lowering diastolic \[Ca^2+^\]~i~, accelerated relaxation of HCM myocardium ([@B16]; [@B28]). Of note, when used in control myocytes and trabeculae, we observed none of the effects shown by ranolazine and GS-967 on action potentials, Ca^2+^-handling and contraction in HCM myocardium ([@B16]; [@B28]); these results highlight the selectivity of these compounds for I~NaL~ over peak I~Na~ and support the idea that I~NaL~ augmentation plays a leading role in the remodeling of cardiac electro-mechanical function in HCM.

Most of the abnormalities of Ca^2+^ handling and contraction we observed in human cardiomyocytes and trabeculae were present also in cardiomyocytes isolated from the hearts of transgenic mice carrying the clinically relevant R92Q mutation of the Troponin T gene ([@B17]; [@B25]): these include slower Ca^2+^-transients, elevated \[Ca^2+^\]~i~, increased I~NaL~ and \[Na^+^\]~i~, as well as impaired relaxation and elevated diastolic tension. Interestingly, in cardiomyocytes from the R92Q mouse, ranolazine hastened Ca^2+^ transients, normalized \[Ca^2+^\]~i~ and \[Na^+^\]~i~ and reduced Ca^2+^-dependent arrhythmias. The observed antiarrhythmic effect of ranolazine may, at least in part, depend on the direct stabilization of ryanodine receptors by the drug ([@B59]), which may have contributed to reduce spontaneous diastolic Ca^2+^ release and arrhythmogenic Ca^2+^ waves in human and mouse HCM cardiomyocytes.

Role of CaMKII in HCM Pathophysiology
=====================================

Sustained activation of the signaling pathways driven by calcium-calmodulin dependent protein kinase II (CaMKII) appear to play a central role as a determinant of cardiomyocyte remodeling and dysfunction in HCM myocardium (**Figure [3](#F3){ref-type="fig"}**), as observed in several human and animal models of cardiac hypertrophy and heart failure ([@B46]; [@B78]; [@B29]). Sustained activation of CaMKII in disease conditions is driven by the increase of cytosolic \[Ca^2+^\]~I~ within the cardiomyocyte, as Ca^2+^-bound calmodulin is the most important activator of this kinase ([@B38]). Additionally, enhanced generation of reactive oxygen species in diseased myocytes, a likely consequence of myocardial energetic derangement, can be a strong contributor to CaMKII over-activation in HCM cardiac muscle ([@B24]). Once activated, CaMKII then phosphorylates itself (at threonine 286 site), thereby prolonging and potentiating its activated state. In HCM vs. control specimens ([@B16]), CaMKII auto-phosphorylation was increased 3.5-fold (**Figure [3A](#F3){ref-type="fig"}**), indicating increased activity ([@B44]). This in turn potentiates the phosphorylation of all the downstream targets of CaMKII ([@B78]; [@B2]; [@B29]). CaMKII targets several proteins involved in the regulation of cardiomyocyte electrophysiology and calcium fluxes. The observed 2.5-fold higher phosphorylation of cardiac Na^+^ channel (NaV1.5) by CaMKII in HCM samples (**Figure [3A](#F3){ref-type="fig"}**; [@B16]) may have significantly contributed to increase I~NaL~ in HCM cardiomyocytes ([@B81]); this suggests that CaMKII activation is the most relevant cause of I~NaL~ augmentation in HCM cardiac myocytes, although additional mechanisms might be involved (e.g., oxidation of Na^+^channels) ([@B47]). The increased phosphorylation of L-Type Ca^2+^ channel (**Figure [3A](#F3){ref-type="fig"}**) may have contributed to slow down I~CaL~ inactivation in HCM cells ([@B39]; [@B84]). The slower I~CaL~ inactivation may also be a consequence of the loss of T-tubules observed in HCM cardiomyocytes (see below) ([@B12]). Moreover, the observed 1.5-fold higher CaMKII-dependent phosphorylation of RyR2 (**Figure [3A](#F3){ref-type="fig"}**) may have contributed to increase the rate of spontaneous releases during diastole ([@B71]) and DADs ([@B20]) in HCM myocytes. Finally, the observed 3-fold higher phosphorylation of PLB at CaMKII site (**Figure [3A](#F3){ref-type="fig"}**), via reduced SERCA inhibition, may have partially counteracted the consequences of reduced SERCA expression in terms of SR Ca^2+^ reuptake, ultimately contributing to maintain SR Ca^2+^ content and steady state Ca^2+^-transient amplitude in HCM cardiomyocytes ([@B53]). In support of the previous observations, we here tested the effects of the acute inhibition of CaMKII in HCM cardiomyocytes and trabeculae by using the cell-permeant version of Autocamtide-related inhibitory peptide II (AIP-II, see **Figures [3B](#F3){ref-type="fig"}--[C](#F3){ref-type="fig"}**). In single human HCM cardiomyocytes, AIP-II reduced diastolic \[Ca^2+^\]~i~ and limited the increase of diastolic \[Ca^2+^\]~i~ at higher stimulation frequencies, without affecting the amplitude or the kinetics of Ca^2+^-transients (**Figure [3B](#F3){ref-type="fig"}**). In line with that, when used in intact human HCM while measuring twitch force, AIP-II reduced diastolic tension and limited the increase of diastolic tension upon increase of pacing rate (**Figure [3C](#F3){ref-type="fig"}**). Interestingly, AIP-II accelerated time-to-peak contraction in HCM trabeculae, suggesting that acute inhibition of CaMKII may directly affect the kinetics of force generation by the myofilaments.

![Increased CaMKII activity underlies electro-mechanical remodeling in HCM cardiomyocytes: acute effects of CaMKII block with Autocamtide 2-related inhibitory peptide II (AIP II) on Ca^2+^ transients and twitch force. **(A)** Right: Representative Western blots (above) for total CaMKII, *(phosphorylated CaMKII at threonine 287 (p-CaMKII), phosphorylated L-type Ca2^+^ channel β2 subunit at threonine 498 (p-LTCCb2), phosphorylated phospholamban at threonine 17 (p-PLB) and phosphorylated ryanodine receptor 2 at serine 2814 (p-RyR2). Average values from septum of control (*n* = 10) and HCM patients (*n* = 10) are reported below. Left: Representative Western blots (above) and mean values (below) for Co-IP of Nav1.5 with CaMKII from control (*n* = 10) and HCM patients (*n* = 10), probed with antibodies for Nav1.5, p-CaMKII and total CaMKII. **(A,B)** For each protein, 5 blots representative of the 10 are shown. Relative intensity of individual bands was quantitated and normalized to GAPDH. The ratio for control was assigned a value of 1. ^∗∗^*P* \< 0.01, *t*-test. Modified from [@B16]. **(B)** Representative Ca^2+^ transients recorded from an HCM cardiomyocytes in the absence and in the presence of AIP II, showing a reduction of diastolic \[Ca^2+^**\]~i~** levels upon administration of AIP II. Data from 19 cells from 4 patients **(C)** Top: Representative force traces from an HCM trabecula in the absence and in the presence of AIPII, showing a reduction of diastolic tension after AIPII and mean diastolic tension at various frequency from 6 HCM trabeculae (5 patients), in the absence and in the presence of AIP II. Bottom: Normalized representative force traces highlighting the effects of AIPII on twitch kinetics and mean data for contraction peak time, at baseline, under AIP II and after washout of the drug **(B**,**C)**. ^\#^*P* \< 0.05 in paired *t*-test. Previously unpublished data.)*](fphys-09-01391-g003){#F3}

Besides the direct effects on cardiomyocyte function, CaMKII is able to alter the expression of genes involved in the hypertrophic remodeling process of cardiomyocytes, and to facilitate the production of collagen, the increase of extracellular matrix volume and the growth of cardiac fibroblasts ([@B43]). We verified that CaMKII participates in the development and progression of cardiac functional and structural phenotype in HCM by studying the transgenic R92Q-TnT mouse model. In the R92Q-TnT mouse, CaMKII activity, increased I~NaL~ and cardiomyocyte Ca^2+^ overload go hand in hand during disease development and are present since the earliest stages of disease development ([@B17]; [@B25]). In this mouse model, lifelong treatment with ranolazine prevented the development of all features of HCM-specific cardiac phenotype, including LV thickening, progression of LV diastolic dysfunction and intra-myocardial fibrosis and the establishment of an arrhythmogenic substrate ([@B17]). The mechanism by which ranolazine prevents the hypertrophic HCM phenotype is related to the inhibition of the enhanced I~NaL~, leading to decreased intracellular \[Na^+^\] and diastolic \[Ca^2+^\]~i~, eventually avoiding the pathological intensification of CaMKII function in treated mice ([@B17]). The reduction of CaMKII-activity in treated mice prevented the progression of the hypertrophic remodeling in mutant hearts, thereby reducing the morphological and functional cardiac HCM-phenotype in mutation-carrier mice.

Loss of T-Tubules in HCM Cardiomyocytes
=======================================

T-tubules ([@B27]) play a fundamental role in myocardial function because they allow a quick propagation of APs within the inner portions of cardiac myocytes. The simultaneous electrical activation of the whole t-tubular system allows for a synchronous triggering of Ca^2+^release from the SR across the whole myocytes, even the central regions that are farther away from surface sarcolemma. This is essential to achieve an homogeneous activation of all myofilaments and thus a rapid simultaneous shortening of the entire cardiac cell. As a proof of concept, by acutely disrupting T-tubules trough osmotic-shock, Ca^2+^release was rendered asynchronous ([@B11]), resulting in a clear impairment of contractile function and a slower relaxation ([@B26]). In cardiomyocytes from animal models of cardiac hypertrophy and heart failure, a delay of local Ca^2+^release was observed both in areas where t-tubules are disrupted ([@B73]) and in regions adjacent to electrically uncoupled T-tubules ([@B67]; [@B18]). [@B48] studied T-tubular structures in myocardial specimens from patients with HF caused by different diseases (i.e., post-ischemic HF, dilated cardiomyopathy and HCM) and observed a significant reduction of T-tubule density in all failing human hearts regardless of the underlying disease, including in end-stage HCM. In a mouse model of HCM we used Random Access Multi Photon (RAMP) microscopy to measure the local propagation of APs in the T-tubule and the correspondent release of Ca^2+^in the adjacent junctional area by simultaneously mapping multiple sites of an isolated cell. With this technique, we found that more than 20% of T-tubules are unable to propagate AP and the surrounding junctional regions display a significantly delayed local Ca^2+^release ([@B19]). In this mouse model, asynchronous intracellular Ca^2+^ release due to altered T-tubules contribute to slow down Ca^2+^-transient kinetics and impair diastolic function.

In all cardiomyocytes subjected to patch-clamp measurements, we measured cell capacitance, an index of sarcolemma extension, and compared with cell volume, as estimated by cell surface (**Figure [4A](#F4){ref-type="fig"}**). The ratio between cell capacitance and volume (surface/volume ratio) was reduced in HCM vs. control human cardiomyocytes, suggesting reduction of T-tubules. In addition, we recently performed a preliminary assessment of the density of T-tubules in cardiomyocytes isolated from surgical septal samples of 10 HCM patient ([@B28]; **Figures [4B,C](#F4){ref-type="fig"}**): in all the myocytes studied under the confocal microscope after membrane fluorescent labeling, we observed a very low density of T-tubules, much lower than what is expected in healthy human cardiomyocytes ([@B48]). We previously demonstrated that the loss of t-tubules may directly contribute to slow down the kinetics of Ca^2+^ transients ([@B26]), thus delaying relaxation, with possible detrimental effects on diastolic function. However, it is unclear whether and how loss of t-tubules affects the propensity toward arrhythmias of HCM cardiomyocytes. Loss of t-tubules could be protective against arrhythmias because orphan RyR channels (RyR uncoupled from t-tubules) have a reduced likelihood of diastolic spontaneous opening ([@B11]); however, the rate of Ca^2+^ waves is increased in human HCM. Loss of t-tubules leads to reduction of capacitance/volume ratio, thus increasing conduction velocity in detubulated myocardial tissue: this effect may prevent the formation of small re-entry circuits. On the contrary, loss of t-tubules may promote arrhythmias because it reduces synchronicity of Ca^2+^ release, thus raising the likelihood of APD and effective-refractory-period (ERP) temporal fluctuations (alternans): APD and ERP alternans facilitate the formation of dynamic reentry circuits ([@B35]). In support of this, we found that Ca^2+^ release is indeed asynchronous in human HCM cardiomyocytes (**Figure [4D](#F4){ref-type="fig"}**). Moreover, loss of t-tubules reduces Ca^2+^-dependent inactivation of I~CaL~, as subsarcolemmal systolic \[Ca^2+^\] is lower below surface sarcolemma than in proximity of T-tubules ([@B55]): indeed, I~CaL~ inactivation is slower in human HCM cells as compared with controls. Finally, the presence of dysfunctional residual t-tubules within the myocyte may facilitate spontaneous Ca^2+^-release events at SR sites adjacent to those tubules, as we previously showed in a model of heart failure ([@B18]), increasing the overall risk of Ca^2+^ waves and DADs.

![The density of T-tubules is markedly low in HCM cardiomyocytes. **(A)** Left: Representative images of a control (top) and an HCM(bottom) cardiomyocyte, showing cell hypertrophy in HCM. Right: surface/volume ratio in HCM and control cardiomyocytes;surface is derived from cell capacitance, volume estimated from cell area. Data from 64 cells (14 patients). Previously unpublished data. **(B)** 2-photon image recorded in HCM intact tissue after membrane labeling with anepp dyes, showing a severe reduction of T-tubules. **(C)**Each cell derives from a different patient sample (ID of the patient is indicated next to the cell in each respective image). Cells were stained with Di-3-ANEPPDHQ (Thermo-Fisher) and imaged with a Leica Confocal microscope using the 488 nm laser line. Sections were taken at mid cell. While the outer sarcolemma is well stained in all myocytes, T-tubules are barely visible in most of them and some cells are completely devoid of T-tubules. White bars equal 10 μm. **(D)** Recordings of intracellular calcium from an HCM myocytes using a fast camera; right: calcium variations during an elicited electrical activation in the subsarcolemma and in the cell core. In agreement with the loss of t-tubule, calcium rise in the core is significantly delayed. Previously unpublished data.](fphys-09-01391-g004){#F4}

Abnormal Response of HCM Myocardium to Beta-Adrenergic Stimulation
==================================================================

We recently investigated the characteristics and anomalies of β-adrenergic signaling in the myocardium of HCM patients by comparing the response of control cardiac muscle to β-adrenergic stimulation with that observed in HCM cardiomyocytes or trabeculae ([@B28]; **Figure [5](#F5){ref-type="fig"}**). In particular, we observed that the mechanical response to the β-adrenergic agonist isoproterenol (that is, augmentation of twitch force amplitude and acceleration of relaxation) was qualitatively similar in HCM and control trabeculae, albeit the kinetics of contraction and relaxation remained slower in HCM myocardium, even upon maximal β-adrenergic activation ([@B28]; **Figures [5A](#F5){ref-type="fig"}--[D](#F5){ref-type="fig"}**). These results suggest that the molecular mechanisms responsible for the acceleration of relaxation upon β-adrenergic activation \[i.e., myofilament Ca2^+^-desensitization ([@B69]) and phospholamban phosphorylation ([@B16]; [@B36])\] are preserved in HCM myocardium.

![Mechanical and electrical response to β-adrenergic stimulation of HCM myocardium. **(A)** Representative superimposed force twitches elicited at 0.5 Hz in control (left) and HCM (right) trabeculae in the absence and presence of Isoproterenol 10^-7^M (Iso). **(B)** Isometric tension during steady state stimulation at 0.5 in the absence and presence of Iso in control and HCM trabeculae. **(C)** Duration of force twitches (from stimulus to 90% of relaxation) elicited at 0.5 Hz in the absence and presence of Isoproterenol 10^-7^M. **(D)** Percentages of Change in the parameters of twitch kinetics (0.5 Hz) upon exposure to Iso in Control (cyan) and HCM (green) trabeculae: time from stimulus to peak contraction (peak time) and time from peak to 50% of relaxation (RT50%). **(E)** Representative superimposed action potentials elicited at 0.5 Hz in control (left) and HCM (right) cardiomyocytes, in the absence and presence of Iso. **(F)** Percentages of Change in the parameters of action potential kinetics upon exposure to Iso in Control (cyan) and HCM (green) cardiomyocytes: time from stimulus to 50% repolarization (APD50%) and time from peak to 90% of repolarization (APD90%). **(G)** Representative superimposed L-Type Ca-current traces at baseline (black traces) and in the presence of Iso (green). **(H)** L-Type Ca-current inactivation time-constant(left) and density (right) at baseline (black) and with Iso (green) in HCM cells. Modified from [@B28].](fphys-09-01391-g005){#F5}

On the contrary The electrical response to isoprenalin observed in single HCM cardiomyocytes was profoundly different as compared with control cardiac cells (**Figures [5E](#F5){ref-type="fig"}--[G](#F5){ref-type="fig"}**). Activation of β-adrenergic receptors physiologically leads to the enhancement of both I~CaL~ and the slow delayed-rectifier K^+^ current (I~Ks~). In healthy human cardiomyocytes the increase of repolarizing K^+^ currents prevails over the augmentation of I~CaL~ ([@B77]), thus determining a net reduction of AP duration ([@B75]; **Figure [5E](#F5){ref-type="fig"}**). In HCM cardiomyocytes, however, we observed unbalanced changes in the expression of Ca^2+^ and K^+^ currents ([@B16]). As shown in **Figure [1](#F1){ref-type="fig"}**, we observed a reduction of the expression of all K^+^ channels (including I~Ks~) while the expression of Ca^2+^ channels and the density of I~CaL~ was slightly increased. Therefore, in response to β-stimulation, the potentiation of I~CaL~ prevails over the increase of K^+^ currents, ultimately causing a net increase of inward currents during the plateau of the AP, thus determining a "paradoxical" prolongation of APD in HCM cardiomyocytes ([@B28]; **Figures [5E,F](#F5){ref-type="fig"}**). Moreover, we observed that β-adrenergic stimulation in HCM cardiomyocytes not only increased peak I~CaL~ amplitude, but also slowed down I~CaL~ inactivation ([@B28]; **Figures [5G,H](#F5){ref-type="fig"}**), further contribute to the prolongation of APs by β-adrenergic agonists. Additionally, recent work suggested that β-adrenergic stimulation is able to rapidly and transiently increase I~NaL~ in cardiac myocytes ([@B23]): a further augmentation of the already increased I~NaL~ in HCM myocytes may have played a relevant role in the paradoxical prolongation of APs with isoprenaline. As expected, AP prolongation by β-adrenergic agonists further increased the occurrence of arrhythmogenic early afterdepolarizations, triggered activity and spontaneous premature contractions in HCM cardiomyocytes and trabeculae ([@B28]). This paradoxical electrical response may have severe consequences in HCM patients, that is, it may increase the risk of exercise/stress-induced arrhythmias in HCM patients.

In parallel, the response of HCM cardiomyocytes to β-adrenergic stimulation in terms of Ca^2+^-handling changes was also abnormal. In HCM cardiomyocytes the β-adrenergic-induced increase of Ca^2+^ release may primarily rely on the prolongation of Ca^2+^ entry via I~CaL~ channels caused by the slower current inactivation. In addition to the increase of net Ca^2+^ influx through I~CaL~, the potentiation of Ca^2+^-entry via reverse-mode NCX may have contributed to the augmentation of Ca^2+^-transients β-receptor activation ([@B61]). The increase of NCX-mediated Ca^2+^-entry upon β-adrenergic stimulation is probably caused by the rise of intracellular \[Na^+^\] in response to the transient augmentation of I~NaL~ and by the further prolongation of AP plateau, as reverse-mode NCX is only active at positive membrane potentials ([@B16]; [@B23]). The idea that the increase of contractile tension in response to β-adrenergic activation mainly depends on the larger Ca^2+^-entry through the sarcolemma apparently contrasts with the largely accepted idea that the inotropic response of β-stimulus mainly stems from the increase of SR Ca^2+^ content ([@B22]), mediated by the enhancement of SR Ca^2+^-uptake by SERCA via PKA-dependent phospholamban phosphorylation, ultimately causing an enhanced release of Ca^2+^ from the SR. The hastening of Ca-transient decay in response to isoprenaline in HCM cardiomyocytes ([@B28]) suggests that the β-adrenergic-induced increase of SERCA function (via PkA-mediated phospholamban phosphorylation) is preserved in HCM myocardium, as Ca-transient decay is physiologically accelerated by isoproterenol. Despite the shortening of Ca^2+^ transient decay, their rise-time is so prolonged that the total duration of Ca^2+^-transients is not reduced upon β-stimulation. The rise of SR Ca^2+^ load upon exposure to isoprenaline in HCM myocytes may be limited by the increased phosphorylation of ryanodine receptors (due to the higher CaMKII activity), which in turn causes a larger rate of Ca^2+^ leakage from the SR during the diastolic period. This may render positive inotropic responses more dependent on the increase of Ca^2+^ entry from the sarcolemma, as the possibility to accumulate Ca^2+^ in the SR is limited. An additional contributor to this aberrant behavior is the lower density of t-tubules observed in HCM myocytes (see above) ([@B58]). The physiological response to β-adrenergic activation may be radically different in disease-remodeled myocytes showing a sparse and disorganized the T-tubular system. In HCM cells, where T-tubules are nearly absent, we expect a large redistribution of I~CaL~ channels to the surface sarcolemma ([@B16]). Under such conditions, modulation of cellularinotropism essentially relies on the magnitude of sarcolemmal Ca^2+^ triggers ([@B26]), that is, the amplitude and duration of I~CaL~ plus the rate of NCX-mediated Ca^2+^ entry (reverse mode). The prolongation of APs causing increased sarcolemmal Ca^2+^-entry appears to be an essential requisite for the preservation of the positive-inotropic effect of β-adrenergic stimulation in HCM myocardium. In line with that hypothesis, the application of ranolazine or GS-967 on top of isoproterenol, which prevented the β-adrenergic-induced AP prolongation, also greatly reduced the positive inotropic response to β-stimulation in HCM myocardium ([@B28]). The preservation of inotropic response in HCM myocardium comes at the expense of a further impairment of diastolic function (due to prolonged Ca^2+^ transient rise-time) and a further increase of the likelihood of cellular arrhythmias (due to increased cytosolic Ca^2+^ accumulation and AP prolongation).

Conclusion
==========

Hypertrophic remodeling in the myocardium of patients with HCM features several pathological alterations of cardiomyocyte electrical function and intracellular Ca^2+^-handling (**Figure [6](#F6){ref-type="fig"}**), that contribute to increase the likelihood of EADs, DADs and premature contractions. Such arrhythmogenic changes occur since the early stages of HCM disease development and may explain the occurrence of ventricular arrhythmias and cardiac arrest in young HCM patients who lack advanced structural alterations of myocardial structure (e.g., diffuse fibrosis, myocardial scars, massive hypertrophy, severe microvascular abnormalities). Changes of the expression and function of ion channels and EC-coupling proteins in HCM myocardium concur to generate an "acquired channelopathy" phenotype in HCM patients that raises the risk of arrhythmias even before the establishment of a structural substrate for sustained arrhythmias. Among the several molecular determinants of cellular arrrhythmogenesis, increased I~NaL~ appear to play a leading role in HCM and may represent a selective target for pharmacological prevention of arrhythmias in this disease, with possible clinical implications. Although targeting I~NaL~ is proven to be effective antiarrhytmic approach, one cannot discount NCX ([@B60]), leaky RyR channels or cardiac CaMKII as potential targets to reduce Ca^2+^-dependent arrhythmias in HCM.

![Functional changes of ion currernts and EC-coupling in human HCM vs. control myocardium (CARTOON).](fphys-09-01391-g006){#F6}
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